Oncodesign selects RIPK2 inhibitors to treat autoimmune and inflammation

, ONCODESIGN, a group specializing in precision medicine biopharmaceuticals, announced the selection of ODS-101 as a candidate for autoimmune and inflammatory disease adaptation.Dr Jane Hoflak, of Oncodesign, explains: "We are excited about the ODS-101 profile and the pharmacological results. Under chronic autoimmune and inflammatory conditions, the compound meets all the stringent standards we set for this application.ODS-101, discovered and selected through Oncodesign's proprietary technology platform, is an efficient selective inhibitor of kinase RIPK2 (the subject interaction protein kinase 2), an essential enzyme for the innate immune system. RIPK2 is a key component in activating the NOD (nucleotide binding oligopolytic domain protein) signaling path path, which plays a key role in the defense mechanism against bacterial infection. In humans, regulating NOD signals is associated with a variety of autoimmune and inflammatory states, including Crohn's disease, ulcerative colitis, Brau syndrome, and early hair nod disease. Other potential adaptations to the de-regulated RIPK2/NOD system inhibit compounds include rheumatoid arthritis and multiple sclerosis. The discovery of ODS-101 will allow Oncodesign to explore these different potential signs in more detail.In June, Oncodesign announced that it was moving its RIPK2 inhibitor program forward to the pre-candidate stage. In the past 6 months, ODS-101 has successfully passed all the criteria required for drug nomination, including preclinical pharmacological model evaluation and two-week oral toxicology studies in rats. ODS-101 is well-to-do, showing promising dose-dependent efficacy in different colitis models, while other studies are still ongoing or planned.Today, Oncodesign has chosen ODS-101 as a state-of-the-art oral RIPK2 inhibitor to drive industrial development research that will rapidly reach its expected industrial status by 2021.Autoimmune and inflammatory diseases (AIIDs) cover more than 150 diseases and account for 5 to 7 per cent of the population in Western countries. They are the largest pharmaceutical market by revenue. In February 2018, the AIID market was valued at $143 billion. However, in many adaptations, current treatments cause partial reactions and require additional differentiated treatment. At present, most treatments are antibody-type and are administered intravenously. Next-generation methods such as oral small molecule kinase inhibitors have the potential to add significant therapeutic value in this area.“ This extraordinary result is the product of the choices and investments we have made over the past 36 months to build a promising portfolio of drug candidates. This RIPK2 kinase inhibitor is a candidate for the first time in our laboratory since 25 years ago. This discovery demonstrates the ability of our nano-ring technology to produce powerful new drug candidates, as well as the relevance of the strategy we deployed in 2010. "It's also a sign of our team's competitiveness in drug discovery, and I would like to congratulate them on their outstanding performance. With our service partnership with Gredma and our search for drug candidates with Serville's LRRK2 targets, we have just adjusted our third plan within the specified timefly period. Our patented RIPK2 inhibitor solves potential pathological problems, making it a potential blockbuster that can change the nature and perception of Oncodesign. Our ongoing efforts are aimed at rapidly delivering treatment options to patients who do not currently have a treatment plan. Dr Philip Genner, Chairman and CEO and Founder of Oncodesign, said: "This success is also a day-to-day thank you to all shareholders and partners for their day-to-day support, for their trust and for the months ahead to prove them right."Dr CSO Jan Hofflack, of Oncodesign, added: "As a state-of-the-art drug, there is still much to be found about other adaptations to our RIPK2 inhibitors. Extensive research is under way to understand the full scope of this innovative approach: ODS-101 has the potential to be a therapeutic breakthrough in addressing many disease adaptations, but the needs of patients remain unsolved. Since 2010, our laboratory has conducted extensive research that has resulted in the first RIPK2 candidate, and I would like to thank all the contributors to the program. We all look forward to ozone-depleting substances-101 moving towards the Declaration on Industrial Development in 2021, possibly managing them among men for the first time in the same year. In addition to ongoing research, we are now stepping up our search for first-class partners to help us develop the full potential of our drug candidates. In particular, we plan to present our plans to several leading companies in the field of autoimmune and inflammatory diseases at the 38th annual J.P. Morgan Healthcare Conference in San Francisco, California, U.S., from January 13 to 16, 2020. ”（cyy123.com）